期刊文献+

血府逐瘀汤联合胺碘酮对不稳定心绞痛的疗效观察 被引量:1

下载PDF
导出
摘要 目的:探究血府逐瘀汤联合胺碘酮对不稳定心绞痛患者的治疗效果。方法:选取2017年6月至2019年9月郑州市中医院收治的不稳定心绞痛患者83例,采用随机数字表法分为两组,对照组采用胺碘酮治疗,观察组采用血府逐瘀汤联合胺碘酮治疗,比较两组患者的心功能、血清脑尿钠肽(BNP)水平及主要心血管不良事件(MACE)发生率。结果:观察组患者总有效率为97.67%高于对照组的80.00%,差异有统计学意义(P<0.05);治疗前两组患者的左室射血分数(LVEF)、心排血量(CO)、左室舒张末内径(LVEDD)及血清BNP水平比较,差异无统计学意义(P>0.05)。治疗后两组患者的LVEF、CO均较治疗前升高,LVEDD及血清BNP水平较治疗前降低,且观察组均优于对照组,差异有统计学意义(P<0.05);观察组MACE发生率低于对照组,差异有统计学意义(P<0.05)。结论:血府逐瘀汤联合胺碘酮可有效改善不稳定心绞痛患者心功能,降低血清BNP水平及MACE发生率。
作者 卢晨君
机构地区 郑州市中医院
出处 《深圳中西医结合杂志》 2020年第19期36-37,共2页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献4

二级参考文献78

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2195

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部